Human Recombinant ALK4 Extracellular Domain

• Description:

  Human Recombinant ALK4 Extracellular Domain _x000D_ Catalog number: B2017043_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 13 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: Activin Receptor-like Kinase 4, Activin Receptor Type-1B, ACTR1B. ACVR1B. ACVRLK4, Serine/threonine-protein Kinase Receptor R2, SKR2_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Lotinun S, Pearsall RS, Horne WC, Baron R. Activin receptor signaling: a potential therapeutic target for osteoporosis Curr Mol Pharmacol. 2012 Jun;5(2):195-204._x000D_ 2: Li J, Fredericks M, Cannell M, Wang K, Sako D, Maguire MC, Grenha R, Liharska K, Krishnan L, Bloom T, Belcheva EP, Martinez PA, Castonguay R, Keates S, Alexander MJ, Choi H, Grinberg AV, Pearsall RS, Oh P, Kumar R, Suragani RN. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders J Clin Invest. 2021 Feb 15;131(4):e138634._x000D_ 3: Calvanese L, Sandomenico A, Caporale A, Focà A, Focà G, D'Auria G, Falcigno L, Ruvo M. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments J Pept Sci. 2015 Apr;21(4):283-93._x000D_ 4: Kumar R, Grinberg AV, Li H, Kuo TH, Sako D, Krishnan L, Liharska K, Li J, Grenha R, Maguire MC, Briscoe SD, Pearsall RS, Herrin BR, Suragani RNVS, Castonguay R. Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily Sci Rep. 2021 Sep 15;11(1):18341._x000D_ 5: Foley SF, van Vlijmen HW, Boynton RE, Adkins HB, Cheung AE, Singh J, Sanicola M, Young CN, Wen D. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis Eur J Biochem. 2003 Sep;270(17):3610-8._x000D_ 6: Lemmens I, Eyckerman S, Zabeau L, Catteeuw D, Vertenten E, Verschueren K, Huylebroeck D, Vandekerckhove J, Tavernier J. Heteromeric MAPPIT: a novel strategy to study modification-dependent protein-protein interactions in mammalian cells Nucleic Acids Res. 2003 Jul 15;31(14):e75._x000D_ 7: Zhao HJ, Klausen C, Li Y, Zhu H, Wang YL, Leung PCK. Bone morphogenetic protein 2 promotes human trophoblast cell invasion by upregulating N-cadherin via non-canonical SMAD2/3 signaling Cell Death Dis. 2018 Feb 7;9(2):174._x000D_ 8: Harrison CA, Gray PC, Fischer WH, Donaldson C, Choe S, Vale W. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors J Biol Chem. 2004 Jul 2;279(27):28036-44._x000D_ 9: Balcioglu O, Heinz RE, Freeman DW, Gates BL, Hagos BM, Booker E, Mirzaei Mehrabad E, Diesen HT, Bhakta K, Ranganathan S, Kachi M, Leblanc M, Gray PC, Spike BT. CRIPTO antagonist ALK4(L75A)-Fc inhibits breast cancer cell plasticity and adaptation to stress Breast Cancer Res. 2020 Nov 13;22(1):125._x000D_ 10: Danila DC, Zhang X, Zhou Y, Haidar JN, Klibanski A. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells J Clin Endocrinol Metab. 2002 Oct;87(10):4741-6. _x000D_ _x000D_ Products Related to Human Recombinant ALK4 Extracellular Domain can be found at Proteins

• Short Description:

  Catalog Number: B2017043 (50 µg)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3